Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
An abstract is available from the original source but is not redistributed by this database. Read the source record.
An abstract is available from the original source but is not redistributed by this database. Read the source record.
Selected source-checked relationships. Keep these records separate, but do not count each report as an independent study or add their participant totals.
The 2017 report follows the original 15-person pilot. Do not combine their sample sizes as independent cohorts. The later randomized smoking trial is separate. Checked 2026-11-03.
Coverage is incomplete. Missing links do not establish independence. Relationship data and source evidence (JSON).
This report is included in a selected evidence comparison. Review its population, primary endpoint, findings and limitations alongside the other selected reports.
These original educational annotations are not an exhaustive systematic review or a clinical guideline.
The listed authors receive credit for the original research. This tracker aggregates source metadata and derives discovery labels; inclusion is not scientific validation.
Checking metadata does not mean individual manual review. Cite the original work for its findings and the exact dataset snapshot and software version for analyses.
Machine-readable provenanceThese labels are search aids derived from indexed metadata, not an assessment of evidence quality. Verify the study design and findings in the original source.
0 referenced DOIs found in stored source metadata. 20 indexed papers cite this DOI.
No close related records were found yet.